Blood cancer sufferers to be offered pioneering new immunity drugs as 'standard care' on NHS following trial success with patients who did not respond to other drugs
Watchdogs last week gave the green light for pembrolizumab after studies suggested patients with Hodgkin's lymphoma on it lived longer than those given radiotherapy and chemotherapy.
Source: dailymail.co.uk